Skip to main content
. 2014 Apr 3;15:107. doi: 10.1186/1745-6215-15-107

Table 4.

Study endpoints

Primary outcome Slope of eGFR over 24 months
Secondary outcomes
Graft and patient survival at 24 months
 
Measured GFR (Cr-51-EDTA method) at 24 months
 
DSA at 6, 12, 18, and 24 months
 
 Mean fluorescence intensity levels
 
 Number of human leukocyte antigen specificities
 
Urinary protein excretion (protein/creatinine ratio) at 6, 12, 18, and 24 months
 
Occurrence of biopsy-proven acute rejection necessitating rejection treatment
 
Acute AMR score in a protocol biopsy performed at 24 months
  Chronic AMR score in a protocol biopsy performed 24 months

AMR, antibody-mediated rejection; Cr-51-EDTA, chromium ethylenediamine tetraacetic acid; DSA, donor-specific antibodies; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate.